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As there is effective intervention for delaying or preventing metabolic diseases, which are often present for years before becoming
clinically apparent, novel biomarkers that would mark metabolic complications before the onset of metabolic disease should be
identified.We investigated the role of fasting serum amino acids and their associations with inflammatorymarkers, adipokines, and
metabolic syndrome (MetS) components in subjects prior to the onset of insulin resistance (IR). Anthropometric measurements,
food records, adipokines, biochemical markers, and serum levels of amino acids were determined in 96 asymptomatic subjects
aged 25–49 years divided into three groups according to the number of MetS components present. Cysteine and tyrosine were
significantly higher already in group with one component of MetS present compared to subjects without MetS components.
Serum amino acid levels correlated with markers of inflammation and adipokines. Alanine and glycine explained 10% of insulin
resistance variability.The role of tyrosine and cysteine, that were higher alreadywith 1 component ofMetS present, should be further
investigated as they might point to future insulin disturbances.
1. Introduction
While people are becoming increasingly less active and more
obese, the incidence of metabolic syndrome (MetS) is grow-
ing at an alarming rate [1]. MetS is a cluster of metabolic risk
factors, including central adiposity, hyperglycemia, hyperten-
sion, and dyslipidemia that occur simultaneously in the same
individual [2, 3]. Its underlying mechanisms remain only
partly understood. However, a strong consensus has been
built on the role of abdominal obesity and insulin resistance
(IR) as pathogenic factors potentially leading to all defining
alteration and to the further development of metabolic dis-
eases [4]. In addition, comparison of obese and lean subjects
has evoked additional hypotheses to explain the pathophys-
iological pathways of obesity associated metabolic disorders
including systemic low-grade inflammation due to changes
in circulating inflammatory cytokines and adipokines [5, 6]
and intestinal microbiota composition [7].
Metabolic diseases (e.g., diabetes) are often present for
years before becoming clinically apparent. At present, clinical
and laboratory predictors such as body mass index or fasting
glucose can be helpful in determining diabetes risk [8], but
they often reflect disease, which is already present. In addi-
tion, IR and type 2 diabetes mellitus (T2DM) might remain
broadly undiagnosed in overweight and obese subjects with
normal blood glucose concentration as they are conditions of
a broadly dysfunctionalmetabolic physiology that in addition
to glucosemetabolism involve considerable changes in amino
acid and fat metabolism [9].
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Given the availability of effective intervention for delaying
or preventingmetabolic diseases [10] and given the increasing
prevalence of obesity worldwide, it remains a challenge to
identify asymptomatic (overweight and obese) individuals
who are at increased risk of developing MetS. Biomarkers
for MetS are potential tools to identify such individuals and
beside IR, several others, including inflammation markers,
markers of lipid peroxidation, adipokines, markers of uric
acids, and some others, have been found to predict the risk
of MetS [4, 11]. Due to comprehensive metabolic profiling
studies, recently, amino acids have been proposed as new
biomarkers reflecting metabolic signatures of insulin action
in obese individuals [12–14].Moreover, a positive relationship
between branched-chain and aromatic amino acids and risk
for future diabetes and IR was demonstrated [15, 16] and
it was found that branched-chain, aromatic amino acids
and orosomucoid were associated with MetS and could be
relevant biomarkers of obesity associated cardiometabolic
disorders [17].
The linkage between some amino acids, obesity, and IR
is well recognized. Moreover, few studies have also evaluated
adipokines and inflammatory cytokines for their sensitivity
to reflect MetS components. However, the relation between
serum amino acids, adipokines, inflammatory cytokines, and
components of MetS in various states of obesity, including
progression from the lean to obese state, prior to the onset
of IR, remains incompletely understood. Therefore, the aim
of the present study was to analyze the associations between
specific amino acids and experimental and clinical measures
such as body shape index (ABSI), blood lipids, inflammatory
markers, and adipokines, which have been confirmed to be
risk factors for MetS, in lean and obese individuals prior to
the onset of IR.
2. Patients and Methods
2.1. Participant Recruitment and Characteristics. A popula-
tion of one hundred eighty-two (70 males and 112 females)
adults, local residents between 25 and 49 years of age,
were enrolled in this cross-sectional study. Subject sampling,
recruitment, and evaluation have been described earlier [18].
Participants were included if they had BMI between 20 and
34.9, did not take any medications for lipid disorders or
anti-inflammatory drugs, did not have any cardiovascular,
endocrine, acute, or chronic inflammatory disease, T2DM,
reported stable weight over the last three months, completed
the questionnaires, and signed an informed consent form
approved by the Slovenian National Medical Ethics Commit-
tee (No. 56/08/11 bis). Ninety-six subjects who met the inclu-
sion criteria were split into three different groups according
to the presence and the number of components ofMetS.MetS
was evaluated according to the Harmonization definition:
hypertriglyceridemia (≥1.7mmol/L), HDL (<1mmol/L in
men and <1.3mmol/L in women), large WC (≥94 cm in men
and ≥80 cm in women), elevated blood pressure (systolic
≥ 130mmHg and/or diastolic ≥ 85mmHg), and elevated
plasma glucose (≥5.6mmol/L) [3]. MetS0 group consisted
of subjects without any component of MetS, in MetS1
group subjects were having one component of MetS, and in
MetS2 group subjects were with 2 and more components of
MetS.
2.2. Anthropometric Measurements and Measurement of Rest-
ing Metabolic Rate. Anthropometric measurements were
obtained using standard protocols and techniques after an
overnight fast by the same, trained, investigator. Subject
height was measured using a Leicester Height Measure
(Invicta Plastics Limited, Oadby, England), with subjects
standing wearing light clothes and no shoes. Weight and
height were measured to the nearest 0.1 kg and 0.1 cm preci-
sion, respectively. Waist circumference (WC) was measured
at the midpoint between the inferior costal margin and
the superior border of the iliac crest on the midaxillary
line, whereas the hip circumference (HC) was measured as
the greatest circumference around the buttocks. BMI was
defined as weight (kg) divided by height squared (m2).
Bioelectrical impedance analysis (BIA) Tanita BC 418MA
(Tanita Corporation, Arlington Heights, IL) was used to
analyze the total body fat and body composition. Obtained
data was analyzed with the provided software. To avoid the
drawbacks regarding the direct relationship between BMI
and WC, ABSI was calculated according to the following
formula: ABSI = WC/(BMI2/3 ⋅ height1/2), with WC and
height expressed in meters and weight in kilograms [19].
In addition, resting metabolic rate (RMR) was deter-
mined using a hand-held indirect calorimeter MedGem
(Medical Home Solutions, Inc., Golden, CO). All RMR
measurements were performed after an overnight fast in a
quiet thermoneutral environment (20–22∘C).
2.3. Dietary Assessment and Physical Fitness Testing. To
assess the energy intake, subjects were asked to write down
a three-day weighed food record for three consecutive days
(including one weekend day). Subjects were fully briefed
on how to complete the diaries by a trained dietitian.
Subjects were asked to continue their normal diet. We
asked them to include food labels and recipes for mixed
dishes in their record. Dietary records were analyzed using
an online, freely assessable, dietary assessment and planning
tool for the analysis of a food diary, named Open Platform
for Clinical Nutrition (OPEN), (http://www.opkp.si/en GB/
cms/vstopna-stran). OPEN food composition data was taken
from the Slovenian food composition database (FCDB)
[20] or if not available here from the Souci-Fachmann-
Kraut FCDB [21] and/or from the USDA National Nutri-
ent Database for Standard Reference (http://www.ars.usda
.gov/Services/docs.htm?docid=8964). Food composition
data applied by the OPEN met the European standard for
food data CEN/TC 387, available at http://www.cen.eu/.
In addition, assessment of aerobic capabilities for each
subject was determined by physical fitness. The participants
had to walk (brisk walking) over 2 km and fitness index
(FI), based on age and BMI, was calculated by scores
of walking time and pulse rate measured at the cervical
aorta. Mentioned program was developed by the UKK
Institute for Health Promotion Research, Tampere, Finland
[22].
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2.4. Biochemical Measurements. After an overnight fasting,
6mL of venous blood was withdrawn by a trained nurse.
Blood samples for biochemical and hormonal determina-
tions were collected in tubes for serum separation. Serum
was separated by centrifugation with coagulated blood at
2000 rpm for 10min at 4∘C. All samples were then frozen and
stored at −20∘C until subsequent analysis. Enzyme-linked
immunosorbent assays (commercially available kits) were
used for measuring serum levels of adiponectin, visfatin,
interleukin 6 (IL-6), resistin, and tumor necrosis factor
𝛼 (TNF-𝛼). Assay sensitivity was 30 pg/mL for visfatin,
10 pg/mL for adiponectin, <1 pg/mL for IL-6, and <2 pg/mL
for TNF-𝛼. Assays interassay and intra-assay CVs were
typically <10%. Fasting serum glucose, C-reactive protein
(CRP), total cholesterol, low density lipoprotein- (LDL-)
cholesterol, high density lipoprotein- (HDL-) cholesterol, and
triacylglycerols were determined using an AU 680 analyzer
(Beckman Coulter) and Olympus reagents. In addition, a
2000 iSR analyzer (Abbott Architect) and Abbott reagents
were used for measuring serum levels of insulin. The estima-
tion of IR was done using the well-established homeostasis
model assessment (HOMA) formula [23].
Serum levels of 10 amino acids (cysteine (Cys), alanine
(Ala), glycine (Gly), leucine (Leu), methionine (Met), pheny-
lalanine (Phe), proline (Pro), serine (Ser), threonine (Thr),
and tyrosine (Tyr)) were analyzed by gas chromatography-
mass spectrometry (GC-MS), as previously described [24].
To sum up, known amounts of 2H
2
-cysteine, 15N-alanine,
15N-glycine, 13C-leucine, [1-13C, methyl-2H
3
]methionine,
13C-phenylalanine, 15N-proline, 15N-serine, 15N-threonine,
and 2H
2
-tyrosine (Cambridge Isotope Laboratories) were
used as internal standards. Serum samples (200𝜇L) with
a known amount of added internal standard were treated
with sulphosalicylic acid (SSA; 200𝜇L, 10%) and then cen-
trifuged and purified on a cationic resin (AG50W-X8; Bio-
Rad, Hercules, CA). After that, samples were lyophilized
and amino acids were derivatized by the addition of
50𝜇L acetonitrile and 50𝜇L MTBSTFA (N-methyl-N-(tert-
butyldimethylsilyl)-trifluoroacetamide) and by heating at
90∘C for 45min. After derivatization, samples were injected
into a GC-MS system (HP 5890, Agilent Technologies, Santa
Clara, CA, USA). Serum concentrations of amino acids were
monitored once; each sample had its own internal standard,
as follows: m/z: Cys m/z 406/408, Ala m/z 158/159, Gly m/z
218/219, Leum/z 302/303, Metm/z 320/324, Phem/z 336/337,
Pro m/z 184/185, Ser m/z 362/363, Thr m/z 404/405, and Tyr
m/z 466/468.
2.5. Statistical Analysis. Variables are presented as means ±
SD.Descriptive statistics were tested before statistical analysis
as being normally distributed; data that was not normally
distributed (serum levels of LDL cholesterol, triacylglycerols,
CRP, insulin, HOMA-IR, visfatin, and TNF-𝛼,) was logarith-
mically transformed for subsequent analysis. To investigate
the metabolic profile in subjects with or without component
ofMetS, subjects were split into three different groups accord-
ing to the presence and the number of components of MetS
(MetS0 group consisted of subjects without any component
ofMetS, inMetS1 group subjects were having one component
of MetS, and in MetS2 group subjects were with 2 and more
components of MetS). Anthropometrical, nutritional, and
physical characteristics and serum metabolites were com-
pared between MetS groups using an independent-sample 𝑡-
test. Pearson’s correlation analyses (crude and adjusted for
age, gender, protein intake, fitness index, and RMR) were
performed to detect different associations between serum
amino acids and components of MetS and/or markers of
inflammation. In addition, hierarchical multiple regression
analysis was used to identify predictors of IR score. SPSS
software (IBM SPSS version 19.0, Chicago, IL) was used for
all analyses. A 𝑃 value of less than 0.05 was considered
statistically significant.
3. Results
3.1. Baseline Characteristics and Physiologic Measures.
Ninety-six subjects underwent baseline evaluation. They
were split into three different groups according to the
presence and the number of components of MetS. MetS0
group consisted of subjects without any component of MetS,
in MetS1 group subjects were having one component of
MetS and in MetS2 group subjects were with 2 and more
components of MetS. MetS0 group comprised 65% women
and MetS1 comprised 69%, whereas MetS2 comprised 67%.
Mean age of subjects in groupMetS2 was 39.5±6.2 years, and
their mean BMI was 29.0 ± 3.5 kg/m2, compared to 36.7 ± 5.6
years and 26.4 ± 4.2 kg/m2 for the subjects in group MetS1
and to 36.6 ± 6.5 years and 21.6 ± 2.2 kg/m2 for the subjects
in group MetS0. Due to the heterogeneity of BMI between
three groups and because of the direct relationship between
BMI and WC, ABSI is added in Table 1. Additional clinical
data are also provided in Table 1.
Based on 3-day food record, subjects in groupMetS2 had
a higher dietary intake of protein (𝑃 = 0.049) and a trend
toward an increase in saturated fat consumption. Physical
activity measured by fitness index was significantly lower
in subjects with components of MetS (MetS1 and MetS2).
However, there was no difference in resting metabolic rate
between studied groups.
Subjects in groups MetS1 and MetS2 had a 37% and 63%
increase in fat mass compared to controls in group MetS0.
Subjects, who had 3 and more (𝑛 = 11) components of
MetS, were also less sensitive to glucose than MetS0 (data
not shown). Indeed, the HOMA-IR index was 2-fold higher
in subjects in group MetS2 than in controls (𝑃 < 0.001). IR
was diagnosed in 5 subjects fromMetS2 (HOMA-IR > 3.60 if
BMI > 27.5 kg/m2 [25]), but mean HOMA-IR was below the
threshold.
3.2. Hormones, Cytokines, and Metabolites. As shown in
Table 2, the adipocyte-derived hormones adiponectin and
visfatin were reciprocally altered by presence of components
ofMetS, such that visfatin levels were 3-fold higher in subjects
in groupMetS2 (𝑃 < 0.001), whereas adiponectin levels were
43% lower (𝑃 = 0.014). Resistin levels were not significantly
different in subjects in groups MetS1 and MetS2 versus
subjects in group MetS0. Among the proinflammatory and
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Table 1: Baseline characteristic and physiologic measures.
Variable
Group
MetS0
𝑁 = 31
MetS1
𝑁 = 35
MetS2
𝑁 = 30
Baseline characteristics
Female 20 (65%) 24 (69%) 20 (67%)
Age (years) 36.6 ± 6.5 36.7 ± 5.6 39.5 ± 6.2
BMI (kg/m2) 21.6 ± 2.2 26.4 ± 4.2b 29.0 ± 3.5d,e
Waist circumference (cm) 74.1 ± 6.7 85.5 ± 9.2b 96.5 ± 8.4d,f
Waist/hip ratio 0.81 ± 0.07 0.85 ± 0.09a 0.90 ± 0.06d,e
ABSI (m11/6/kg2/3) 0.073 ± 0.005 0.074 ± 0.005 0.077 ± 0.004d,f
Systolic blood pres. (mmHg) 119 ± 14 122 ± 13 134 ± 20
Diastolic blood pres. (mmHg) 67 ± 6 73 ± 12 80 ± 12c
Pulse (rate/min) 58 ± 25 55 ± 29 66 ± 9c,e
Smoking (%)
Yes 19 17 10
No 81 83 90
Dietary intake
Total energy (kcal/day) 1950 ± 500 2050 ± 650 2100 ± 700
Total carbohydrate (g/day) 240 ± 70 250 ± 100 250 ± 100
Total fiber (g/day) 23 ± 11 21 ± 7 23 ± 10
Total protein (g/day) 75 ± 25 85 ± 30 90 ± 40c
Total fat (g/day) 75 ± 25 80 ± 30 80 ± 30
Total saturated fat (g/day) 23 ± 10 25 ± 10 28 ± 12
Polyunsaturated fat (g/day) 11 ± 5 11 ± 5 11 ± 6
Physical status
Fitness index 110 ± 15 90 ± 15a 80 ± 15c
Body composition
Body fat (%) 21.9 ± 6.6 29.9 ± 10.1a 35.6 ± 9.5d,e
Resting metabolic rate
RMR (kcal/day) 1470 ± 300 1440 ± 300 1450 ± 400
Insulin resistance
HOMA-IR 1.2 ± 0.5 1.4 ± 0.5 2.5 ± 1.2d,f
ABSI: a body shape index; BMI: body mass index; HOMA-IR: insulin resistance score; RMR: resting metabolic rate.
Values are presented as means ± SD.
a,bGroup MetS1 is significantly different from group MetS0 at 𝑃 < 0.05 and 𝑃 < 0.001, respectively.
c,dGroup MetS2 is significantly different from group MetS0 at 𝑃 < 0.05 and 𝑃 < 0.001, respectively.
e,fGroup MetS2 is significantly different from group MetS1 at 𝑃 < 0.05 and 𝑃 < 0.001, respectively.
anti-inflammatory cytokines measured, TNF-𝛼 and CRP dif-
fered between three studied groups. Furthermore, CRP levels
were 3-fold and 4.5-fold higher in group MetS1 and group
MetS2, respectively.Mean fasting blood glucose, insulin, total
cholesterol, LDL-cholesterol, and triacylglycerols levels were
higher in group MetS2 compared to group MetS0. On the
other hand, HDL-cholesterol and bilirubin levels were lower
in group MetS2, compared to group MetS1 and MetS0. We
measured serum amino acids by tandem mass spectrometry.
Among a total of 10 amino acids measured, 3 were not
different in subjects having 1, 2, or more components of MetS
versus control subjects (Thr, Pro, and Met). Five other amino
acids were elevated in subjects having components of MetS
versus controls (Ala, Leu, Phe, Tyr, and Cys), whereas Gly
and Ser levels were lower in these subjects. Cys and Tyr
were significantly higher already inMetS1 compared toMetS0
(Table 2).
3.3. Evaluation of the Associations between Amino Acids and
Components of MetS. Changes in blood concentrations of
Ala, Gly, Leu, Cys, Tyr, and Phe were apparent with obesity
and IR.
3.4. Associations between Sulfur AminoAcids andComponents
of MetS and Markers of Inflammation. Evaluation of the
associations between Cys and Met with parameters of body
composition reveals significant strong associations between
Cys and BMI, body fat, and WC, as observed in Tables 3
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Table 2: Adipokines, cytokines, and metabolites.
Variable MetS0
𝑁 = 31
MetS1
𝑁 = 35
MetS2
𝑁 = 30
Adipokines
Adiponectin (mg/L) 6.5 ± 3.2 6.3 ± 4.6 3.7 ± 2.5c,e
Visfatin (𝜇g/L) 0.33 ± 0.22 0.60 ± 0.43b 0.96 ± 0.53d,e
Resistin (mg/L) 8.2 ± 2.6 8.0 ± 2.1 8.0 ± 3.4
Markers of inflammation
C-reactive protein (mg/L) 0.7 ± 0.6 2.0 ± 1.8b 3.1 ± 2.1d,e
IL-6 (ng/L) 3.0 ± 0.8 3.0 ± 1.0 4.3 ± 1.1
TNF-𝛼 (ng/L) 2.0 ± 1.6 4.2 ± 2.2a 4.7 ± 2.1c
Conventional metabolites
Glucose (mmol/L) 4.9 ± 0.4 5.1 ± 0.3 5.4 ± 0.5c,e
Insulin (𝜇U/mL) 5.4 ± 1.9 7.3 ± 2.8a 13.0 ± 5.8d,e
Total cholesterol (mmol/L) 4.9 ± 0.8 5.4 ± 1.0 5.6 ± 1.2c
HDL-cholesterol (mmol/L) 1.6 ± 0.2 1.5 ± 0.3 1.2 ± 0.3c,e
LDL-cholesterol (mmol/L) 3.0 ± 0.7 3.4 ± 0.9 3.6 ± 1.1c
Triacylglycerols (mmol/L) 0.8 ± 0.2 1.0 ± 0.4a 1.7 ± 0.8d,f
Homocysteine (𝜇mol/L) 10.8 ± 2.6 9.6 ± 2.6 10.4 ± 2.5
Bilirubin (𝜇mol/L) 14.5 ± 5.6 14.9 ± 6.5 11.9 ± 3.3c,e
Amino acids in serum (𝜇mol/L)
Alanine 365 ± 72 389 ± 87 426 ± 75c
Glycine 274 ± 64 255 ± 73 230 ± 46c
Leucine 119 ± 18 124 ± 20 158 ± 30c
Phenylalanine 59 ± 8 63 ± 8 67 ± 6c
Tyrosine 54 ± 13 64 ± 11a 72 ± 10d,e
Threonine 134 ± 32 132 ± 23 131 ± 17
Serine 119 ± 17 116 ± 22 105 ± 11c
Proline 175 ± 63 172 ± 32 203 ± 43
Methionine 22 ± 5 23 ± 5 24 ± 3
Cysteine 0.3 ± 0.3 3.0 ± 2.7b 5.8 ± 4.7d,e
HDL: high density lipoprotein; IL: interleukin; LDL: low density lipoprotein; TNF: tumor necrosis factor.
Values are presented as means ± SD.
a,bGroup MetS1 is significantly different from group MetS0 at 𝑃 < 0.05 and 𝑃 < 0.001, respectively.
c,dGroup MetS2 is significantly different from group MetS0 at 𝑃 < 0.05 and 𝑃 < 0.001, respectively.
e,fGroup MetS2 is significantly different from group MetS1 at 𝑃 < 0.05 and 𝑃 < 0.001, respectively.
and 4. Furthermore, evenwhen adjusting for age, gender, pro-
tein intake, RMR, and FI, significant associations remained
between Cys and HOMA (Table 3; 𝑟 = 0.443, 𝑃 = 0.001),
CRP (Table 3; 𝑟 = 0.378, 𝑃 = 0.003), WC (Table 3; 𝑟 = 0.512,
𝑃 < 0.001), ABSI (Table 3; 𝑟 = 0.323, 𝑃 = 0.002), TNF-
𝛼 (Table 3; 𝑟 = 0.259, 𝑃 = 0.038), and HDL-cholesterol
(Table 3; 𝑟 = −0.281, 𝑃 = 0.032). On the other hand, we
did not observed any significant association between serum
levels ofMet and components ofMetS nor forMetmetabolite,
homocysteine (data not shown).
3.5. Associations between Tyr and Phe and Components of
MetS and Markers of Inflammation. Evaluation of the asso-
ciations between Tyr with components of MetS reveals
significant strong associations between Tyr and WC, body
fat, SBP, glucose, triacylglycerols, HDL-cholesterol, CRP,
HOMA, adiponectin, and TNF-𝛼, as observed in Table 3
and Figure 1. Furthermore, even when adjusting for age,
gender, protein intake, RMR, and FI, significant associations
remained between Tyr and HOMA (Table 3; 𝑟 = 0.313, 𝑃 =
0.020), CRP (Table 3; 𝑟 = 0.293, 𝑃 = 0.029), WC (Table 3;
𝑟 = 0.5040, 𝑃 < 0.001), ABSI (Table 3; 𝑟 = 0.273, 𝑃 = 0.009),
and TNF-𝛼 (Table 3; 𝑟 = 0.164, 𝑃 = 0.027).
Phe was also associated with different components of
MetS, but when these associations were adjusted for age, gen-
der, protein intake, RMR, and FI, only associations between
Phe andWC (Table 3, Figure 1; 𝑟 = 0.362, 𝑃 = 0.006), glucose
(Table 3; 𝑟 = 0.321, 𝑃 = 0.014), TNF-𝛼 (Table 3; 𝑟 = 0.282,
𝑃 = 0.035), and HDL-cholesterol (Table 3; 𝑟 = −0.271,
𝑃 = 0.038) remained significant.
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Figure 1: Associations between aromatic amino acids and components of MetS. Evaluation of the associations between tyrosine with
components of MetS reveals significant strong associations between tyrosine and waist circumference (𝑟 = 0.621, 𝑅2 = 0.380; 𝑃 < 0.001) (a),
body mass index (𝑟 = 0.550, 𝑅2 = 0.302; 𝑃 < 0.001) (b), and % of body fat (𝑟 = 0.733, 𝑅2 = 0.536; 𝑃 < 0.001 for male subjects; 𝑟 = 0.458,
𝑅
2
= 0.210; 𝑃 = 0.002 for female subjects) (d). A significant strong association between phenylalanine and waist circumference is evident
in (c) (𝑟 = 0.411, 𝑅2 = 0.169; 𝑃 < 0.001). I, male subjects; ◼, female subjects. Associations were analyzed by Pearson’s correlation analyses
(crude). A 𝑃 value of less than 0.05 was taken as a statistically significant difference between the tested parameters.
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Figure 2:Associations between leucine and components of MetS, waist circumference (a) and HDL-cholesterol (b). Evaluation of the association
between leucine and components of MetS reveals a significant relationship between leucine and waist circumference (𝑟 = 0.546, 𝑅2 = 0.298;
𝑃 < 0.001) (a) and leucine and HDL-cholesterol (𝑟 = −0.341, 𝑅2 = 0.116; 𝑃 = 0.001) (b). I, male subjects; ◼, female subjects. Associations
were analyzed by Pearson’s correlation analyses (crude). A 𝑃 value of less than 0.05 was taken as a statistically significant difference between
the tested parameters.
Table 4: Association of cysteine andmethionine with parameters of
body compositiona.
Methionine
(𝜇mol/L)
Cysteine
(𝜇mol/L)
Cysteine (𝜇mol/L) 0.14c —
BMI (kg/m2) 0.06 0.52
Body fat (%) −0.05 0.48
Serum vitamin B12 (pg/mL) 0.20 0.04
Serum folic acid (𝜇g/L) −0.09 0.19
aPearson correlation coefficients, adjusted for age and gender.
Bold entries indicate significant correlations (𝑃 < 0.001 unless otherwise
stated).
c
𝑃 < 0.05.
3.6. Associations between Leu and Components of MetS and
Markers of Inflammation. Furthermore, evaluation of the
association between Leu and components of MetS reveals
a significant relationship between Leu and WC (Table 3,
Figure 2; 𝑟 = 0.546, 𝑃 < 0.001), Leu and ABSI (Table 3;
𝑟 = 0.311, 𝑃 = 0.007), Leu and HOMA (Table 3; 𝑟 =
0.297, 𝑃 = 0.004), Leu and glucose (Table 3; 𝑟 = 0.341,
𝑃 = 0.001), Leu and triacylglycerols (Table 3; 𝑟 = 0.223,
𝑃 = 0.032), Leu and HDL-cholesterol (Table 3, Figure 2;
𝑟 = −0.341, 𝑃 = 0.001), and Leu and systolic blood pressure
(SBP) (Table 3; 𝑟 = 0.300, 𝑃 = 0.003) but also between Leu
and adiponectin (Table 3; 𝑟 = −0.384, 𝑃 = 0.001) and TNF-
𝛼 (Table 3; 𝑟 = 0.220, 𝑃 = 0.039). When adjusting for age,
gender, protein intake, RMR, andFI,we confirmed significant
relationships between Leu and HOMA (Table 3; 𝑟 = 0.351,
𝑃 = 0.008), Leu and WC (Table 3; 𝑟 = 0.493, 𝑃 < 0.001),
Leu and ABSI (Table 3; 𝑟 = 0.272, 𝑃 = 0.009), Leu and
adiponectin (Table 3; 𝑟 = −0.273, 𝑃 = 0.038) and TNF-𝛼
(Table 3; 𝑟 = 0.312, 𝑃 = 0.012), and Leu and serum glucose
(Table 3; 𝑟 = 0.391, 𝑃 = 0.003) andHDL-cholesterol (Table 3;
𝑟 = −0.286, 𝑃 = 0.026).
3.7. Associations between Other Amino Acids and Components
of MetS and Markers of Inflammation. Evaluation of the
associations between Gly and components of MetS and
markers of inflammation reveals significant strong negative
associations between Gly andWC, SBP, triacylglycerols, CRP,
and HOMA-IR, as observed in Table 3. Furthermore, even
when adjusting for age, gender, protein intake, RMR, and FI,
significant negative associations remained between Gly and
WC (Table 3, Figure 3; 𝑟 = −0.311, 𝑃 = 0.016), ABSI (Table 3;
𝑟 = −0.231,𝑃 = 0.025), CRP (Table 3; 𝑟 = −0.381,𝑃 = 0.004),
and triacylglycerols (Table 3; 𝑟 = −0.363, 𝑃 = 0.006).
Ala was significantly associated with SBP, visfatin, glu-
cose (Figure 3), triacylglycerols, and HOMA-IR, and after
adjusting for age, gender, protein intake, RMR, and FI, Ala
remained significantly associated with visfatin, glucose, and
triacylglycerols.
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Figure 3: Associations between glycine and waist circumference (a) and between alanine and glucose (b). A significant relationship between
glycine and waist circumference is evident in (a) (𝑟 = −0.348, 𝑅2 = 0.121; 𝑃 = 0.001) and a significant relationship between alanine and
glucose in (b) (𝑟 = 0.429, 𝑅2 = 0.184; 𝑃 < 0.001). I, male subjects; ◼, female subjects. Associations were analyzed by Pearson’s correlation
analyses (crude). A 𝑃 value of less than 0.05 was taken as a statistically significant difference between the tested parameters.
Hierarchical multiple regression analysis was performed
to examine the effects of traditional parameters and amino
acids on the level of IR score (Table 5). First the general
parameters (age and gender) were entered as control variables
(step 1), followed by components of MetS (WC, fasting
serum concentration of glucose, HDL-cholesterol, and blood
pressure) (step 2). Then specific amino acids were entered
(step 3).The hierarchical multiple regression revealed that, at
stage one, general parameters, for example, age and gender,
contributed to the regression model and accounted for 6%
of the variation in IR score. Introducing obesity parameters
in stage two of the regression model explained 44% of the
variation in IR score and two important predictors of IR
score were confirmed (WC and fasting serum glucose). In
addition, the results of the regression in step 3 indicated that
serum levels of amino acids explained an additional 10% of
the variation in IR score and change in 𝑅2 was significant
(𝑃 < 0.001). To sum up, as explained in Table 5, it was found
that IR score was significantly predicted by WC (𝛽 = 0.565,
𝑃 < 0.001), more than by fasting glucose (𝛽 = 0.382, 𝑃 <
0.001), serum Gly (𝛽 = −0.188, 𝑃 < 0.05), and serum Ala
(𝛽 = 0.161, 𝑃 < 0.05). Together, the adjusted 𝑅 squared value
was 0.60. This indicates that 60% of the variance in IR score
was explained by the model.
4. Discussion
Increasingly overweight and obese population faces higher
incidence of IR and related complications. IR is caused by
toxic metabolic by-products that are a consequence of ele-
vated dietary nutrients exposure of tissues, caused by obesity
and overnutrition, and impaired interorgan communication
networks that include hormones and cytokines [5]. As we
examined the asymptomatic population, in which interven-
tions can reverse the abrupt state, it is important to have a
broad set of potential biomarkers. As Adams (2011) reports,
millions of overweight to moderately obese subjects remain
undiagnosed as prediabetics, as they have normal glucose
levels, although they have disrupted metabolism [9]. How
do the serum amino acids and adipokine relations change
while progressing from the lean to obese state prior to the
onset of IR? While the adipokine profiles of metabolic com-
plications have been extensively studied, metabolic profiling
is emerging as a way to get new insights into mechanism of
obesity-relatedmetabolic changes.We evaluated serum levels
of 10 amino acids (Ala, Gly, Leu, Phe, Tyr, Thr, Ser, Pro, Met,
and Cys) in asymptomatic adult population from Slovenia
and found clear associations between a subset of amino acids
and MetS characteristics. The participants were divided into
three groups according to the number of components ofMetS
present.
When serum concentrations of the analyzed amino acids
were compared, statistically significantly higher levels in
MetS2 group compared to MetS0 group were observed for
Cys, Tyr, Ala, Leu, and Phe while Gly and Ser levels were
statistically significantly lower. Differences were observed
also for CRP and TNF-𝛼 that were statistically significantly
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Table 5: Results of hierarchical multiple regression analysis for
variables predicting insulin resistance score.
Predictors
Dependent variable: insulin
resistance score
𝛽 𝐹 Δ𝑅
2
Step 1 2.82 0.06
Age (years) 0.167
Gender −0.201
Step 2 15.99 0.44∗∗∗
Waist circumference (cm) 0.565∗∗∗
Systolic blood pres. (mmHg) 0.085
Diastolic blood pres. (mmHg) 0.013
Fasting glucose (mmol/L) 0.382∗∗∗
HDL-cholesterol (mmol/L) −0.104
Step 3 13.45 0.10∗∗∗
Alanine (𝜇mol/L) 0.161∗
Glycine (𝜇mol/L) −0.188∗
Leucine (𝜇mol/L) 0.020
Tyrosine (𝜇mol/L) 0.086
Cysteine (𝜇mol/L) 0.043
Total 𝑅2 0.60∗∗∗
𝑁 96
∗
𝑃 < 0.05, ∗∗𝑃 < 0.01, and ∗∗∗𝑃 < 0.001.
higher, while the difference in IL-6 was not statistically
significant. Similar picture was observed when assessing
adipokine signaling: adiponectin was significantly lower in
MetS2 group (nonpublished data) while visfatin was signif-
icantly higher [18]. Similarly to previous reports [26, 27],
we observed no difference in resistin levels between the
three groups in the present study, although some studies
demonstrated significantly higher serum resistin levels in
MetS group compared to control group [28, 29]. Interestingly,
some parameters were statistically higher already when the
groups MetS0 and MetS1 were compared. These were CRP,
TNF-𝛼, visfatin, insulin, triacylglycerols, which have been
already discussed as biomarkers, and Tyr and especially Cys.
To get a better insight into the relations between serum amino
acids and immune and adipose signaling, we assessed these
correlations for selected amino acids, with an emphasis on
Cys and Tyr.
Cys levels in our subjects were significantly higher with
growing number of MetS components: in group MetS1,
they were 10-fold higher than in group MetS0, while in
group MetS2 they were 19.3 times higher than in the group
MetS0. High plasma Cys showed being linked to obesity,
Cys might even cause obesity and have an insulin-like action
on adipocytes [30]. Total Cys showed having strong positive
correlation with fat mass and being a stronger predictor of
fat mass than serum lipids such as triacylglycerols, HDL,
and total cholesterol [31]. We found significant positive cor-
relations between serum Cys and HOMA-IR, CRP, TNF-𝛼,
WC, and ABSI and significant negative correlations between
Cys and HDL-cholesterol. Serum Cys imbalances therefore
correlate with markers of metabolic dysfunction. We found
Cys significantly higher already in the group with only one
MetS component present.The difference in Cys was the high-
est difference between the groups MetS0 and MetS1. Groups
MetS0 andMetS1 significantly differed in conventionalmark-
ers of adiposity (BMI,WC, waist/hip ratio, and body fat (%)),
fitness index, and O
2
expenditure and in levels of CRP, TNF-
𝛼, visfatin, insulin, and triacylglycerols, but there were no
statistically significant differences in ABSI. Since ABSI is an
index of both visceral obesity and decreasedmusclemass [19],
this could suggest that Cys levels changes are apparent before
the catabolic changes in muscle (sarcopenia). Is the increased
serum cysteine an early marker of a metabolic dysfunction,
before the very onset of the MetS? Cys is involved in body’s
antioxidant defense as one of the amino acids involved in
synthesis of glutathione (GSH), together with glutamate and
glycine. In glucagon high states or in T2DM, Gly might
become a limiting factor in GSH synthesis [32].
In the present study, serum Gly was lower with increasing
number of components ofMetS andwas negatively associated
with WC, serum triacylglycerols, and CRP. Although Gly is a
glucogenic amino acid and the gluconeogenesis from amino
acids is elevated in obese people, serum Gly concentration
is lower in obese people due to their higher level of fasting
insulin which is responsible for lower contribution of Gly to
glucose production and higher glycogen stores [33]. Serum
Gly in our participants was significantly lower in MetS2
compared to MetS0 group implying the insulin imbalance,
despite the mean HOMA-IR for the latter group being below
the threshold value for IR [25]. Serum Gly concentration
was found as the only HOMA-IR associated predictor of
both intramuscular adipose tissue (IMAT) and abdominal
adiposity in functionally limited overweight older adults [34].
It negatively correlated with IMAT and positively correlated
with subcutaneous adipose tissue [34]. In our study, Gly
statistically negatively correlated with ABSI, a marker of
visceral adiposity and decreasedmusclemass, andCRP, while
we found statistically significant correlation between Gly and
HOMA-IR only before adjusting for age, gender, protein
intake, and FI. Nevertheless, we found lower Gly as the most
important predictor for both HOMA-IR and CRP in our
asymptomatic younger adult population. Inflammation has
an apparent role in metabolic dysfunction: high doses of
salicylates or derivatives reversed IR in obese rodents [35]
and also in nondiabetic insulin-resistant obese adults [36].
Growing evidence shows that Gly supplementation may be
a novel therapy for obesity and T2DM. Specifically, dietary
supplementation with Gly decreases concentrations of free
fatty acids and triacylglycerols, as well as adipocyte size and
adiposity in an animal model of intraabdominal obesity [37].
The beneficial effects of Gly in obesity and T2DM therapy can
result from improved insulin sensitivity [38], increased anti-
inflammatory capacity [39], and normalization of secretion
of triacylglycerol-rich very low density lipoproteins from the
liver by triggering neuronal transmission in the dorsal vagal
complex through the𝑁-methyl-𝐷-aspartate receptor [40].
Sulphur-containing amino acids levels were reported to
be increased in obese people, people with IR state and
T2DM [9]. Although we observed substantially higher levels
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of Cys with growing number on MetS components, no
significant association between serum levels of Met and
components of MetS was observed in our normal and
overweight asymptomatic population. However, Met is an
essential amino acid whose metabolism is tightly regulated.
Its metabolite, homocysteine, can be either remethylated
to methionine or undergo transsulfuration to form cys-
teine [41]. As J. T. Brosnan and M. E. Brosnan explained,
remethylation depends mainly on methionine synthase, an
enzyme dependent on vitamins B2, B6, B9, and B12 [41].
The deficiency of those vitamins is associated with elevated
plasma homocysteine levels. We observed no difference in
homocysteine levels between the three groups in the present
study. Similarly, homocysteine levels remained unchanged or
were even lower in IR andT2DMwithout renal complications
[42]. Transsulfuration, on the other hand, is increased in
high Met levels, in high protein diet, and by peroxides while
being decreased by antioxidants [40]. There were significant
differences in protein intake between the groups. Protein
intake was statistically higher in group MetS2 than in group
MetS0. A trend in higher protein intake in group MetS1 was
also observed, although the differences were not statistically
significant. Indeed, high Cys obtained from high protein
intake promotes adiposity and adverse metabolic pheno-
type in mice, indicating the positive association of plasma
Cys with obesity in humans [43]. There was also a trend
toward higher saturated fat consumption from group MetS0
to group MetS2, but the differences were not statistically
significant. The differences and trends in protein and fat
intake could explain the unchanged Met and homocysteine
concentrations across the three groups. It could be caused
by the increased rate of transsulfuration of homocysteine to
Cys.
The other serum amino acid that was statistically signif-
icantly higher already in group MetS1 compared to MetS0
was Tyr. Its serum level was even higher in group MetS2; the
difference from MetS1 was statistically significant. Tyr levels
correlated withWC, ABSI, TNF-𝛼, CRP, and HOMA-IR. Lit-
erature suggests a link between Tyr metabolism and insulin
signaling. Tyr aminotransferase, which catalyzes the first step
in degradation pathway that converts Tyr to fumarate and
acetoacetate, has been well studied as a target of regulation
by insulin signaling in cell models with insulin effects seen at
the transcriptional and translational level [44–46]. However,
a direct connection between Tyr aminotransferase and Tyr
metabolism on insulin action in vertebrates has not been
demonstrated. But recently Ferguson et al., based on their
finding, proposed a novel role for Tyr as a developmental
regulator where elevated Tyr levels play a causal role in the
development of diabetes and cancer in people [47].
Also the levels of the other aromatic amino acid,Phe, were
elevated in group MetS2 compared to MetS0. In accordance
with our results, increased circulating concentrations of Tyr
and Phe have often been reported in the obese, insulin-
resistant, or diabetes state in humans [13, 48, 49].
However, the metabolic pathways of amino acids are
interconnected, so literature reports more amino acids to
be associated with IR or glucose impaired states. Branched-
chain amino acids (BCAA: Val, Leu, and isoleucine (Ile))
affect the availability of aromatic amino acids by competing
with them for the large neutral amino acid transporter
(LAT1) [50, 51]. We also found positive associations between
aromatic amino acids (Tyr and Phe) and components ofMetS
and insulin-resistant state. In accordance with our results,
Wang et al. demonstrated that Ile, Phe, and Tyr are predictors
for future diabetes with a more than fivefold higher risk
[15]. In addition, it was found in a recent study that BCAA,
aromatic amino acids, and orosomucoid are associated with
MetS and could be relevant biomarkers of obesity associated
cardiometabolic disorders [17]. Increased fasting aromatic
amino acids and BCAA were reported as predictors for IR
in both cross-sectional and 6-year longitudinal analysis of
young normoglycaemic adults [16]. In themetabolomic study
conducted by Newgard et al., principle component analysis
showed that the component comprising aromatic amino
acids, BCAA, and BCAA by-products were most strongly
associated with obesity and positively linked to HOMA-
IR [13]. How changes in Phe and Tyr metabolism could
contribute to development of metabolic disease is currently
unknown.
Of the BCAA, in the present study the concentration
of Leu was determined. Leu serum concentration was sta-
tistically higher in MetS2 than in MetS0. It statistically
significantly correlated with WC, ABSI, TNF-𝛼, glucose,
and HOMA-IR and negatively correlated with adiponectin
and HDL-cholesterol (after the adjustment for age, gender,
protein intake, RMR, and FI), all markers of a metaboli-
cally disrupted state. Higher serum Leu concentrations in
metabolically disrupted states were reported previously [13].
Newgard and coauthors proposed that increasedBCAA levels
activate the mammalian target of rapamycin/protein 6 kinase
1 (mTOR/S6K1) pathway and phosphorylation of insulin
receptor substrate 1 (IRS1) on multiple Ser, contributing to
IR [13]. However, whether enhanced BCAA concentrations
in blood serum are the reason or the cause of insulin
insensitivity is not clear yet [9]. There is a lot of evidence of
positive effect of Leu supplementation on metabolic health
[52, 53]. However, the effects of dietary protein on metabolic
health are not clear yet. In the present study, it is evident that
individuals with 2 or more components of MetS consumed
more protein than lean individuals in group MetS0 and
association between protein intake and Leu levels in group
MetS2 remained significant even after adjustment for age,
gender, energy intake, and physical activity. Is higher dietary
protein intake responsible for higher fasting serum Leu and
observed higher fasting serum concentrations of other amino
acids? Leu is an essential amino acid; thus dietary protein
could have a significant impact on Leu in humans. However,
as suggested, most metabolomics experiments (including the
present) are performed in fasted state, so it is not likely
that the observed serum amino acid levels are dependent
on dietary amino acid [9]. Another potential explanation for
higher fasting Leu in the present study could be impaired
BCAA catabolism. In obese cotwins, decreased adipose
tissue BCAA catabolism that correlated with critical clinical
measures of obesity was observed compared to nonobese
cotwins [54]. Further, in obese subjects, accelerated pro-
tein catabolism in muscle and muscle wasting is present
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due to disuse in sedentary lifestyle or due to systemic
low-grade inflammation or combination of both (sarcopenic
mechanisms are revised in [55]). Adams explains impaired
amino acidmetabolism by impaired insulin action, increased
FFA oxidation, and cooccurring changes in mitochondrial
redox status (which is shifted in a more reducing state) that
attenuate specific catabolic pathways (blocking BCKD and
PDH) that in turn increase tissue and blood concentrations of
BCAA, sulphur amino acids, aromatic amino acids Phe and
Tyr, and related derivatives [9].
Increased BCAA catabolic flux might contribute to
increased gluconeogenesis and glucose intolerance via glu-
tamate transamination to Ala [13]. The first step of BCAA
catabolism produces Glu (due to technical restrictions we do
not have the data for its concentration); the accumulation of
the latter might increase the transamination of pyruvate to
Ala [51].We found statistically significantly higher serumAla
levels in group MetS2 than in group MetS0. Ala levels pos-
itively correlated with visfatin, glucose, and triacylglycerols
after adjusting for age, gender, protein intake, RMR, and FI.
In catabolic states, circulatingAla increases, acting as a carrier
of amino acids from muscle to liver, where gluconeogenesis
takes place. As She et al. summarized the research from
four decades ago, this increase of circulating Ala can be
due to transamination of glucose-derived pyruvate carrier
in increased muscle catabolism or from transamination of
pyruvate derived from glycolysis [56]. Could higher Ala
level in group MetS2 point to a higher muscle catabolism
in subjects in group MetS2? Group MetS2 had, indeed,
significantly higher ABSI compared to MetS0 and MetS1
althoughAla levels did not correlate withABSI.We foundAla
as important predictor of HOMA-IR. This is in accordance
with a cross-sectional study of 263 nonobese Asian Indian
and Chinese men, in which IR was significantly associated
with the increased levels of Ala, Pro, Val, Leu/Ile, Phe, Tyr,
glutamate/glutamine, and ornithine [14].
5. Conclusions
Overall, above cited and our results point to perturbation
of amino acid metabolism in subjects with metabolic dis-
ease. However, in the present study, perturbation of Cys,
Tyr, Ala, Leu, Phe, Gly, and Ser metabolism was observed
in individuals with only 2 components of MetS, prior to
the onset of metabolic disease. Further, Cys and Tyr were
significantly higher already with one component of MetS
present. We found correlations between Cys and Tyr and
markers of inflammation, CRP and TNF-𝛼. One of the
potential mechanisms contributing to MetS is dysregulation
of the adipose tissue and increased cytokine production [53].
So, our findings indicate that altered Cys and Tyr in serum
not only are associated with IR, but also are closely related
to inflammatory markers. Taken together, these results may
indicate that altered Cys and Tyr metabolism are associated
with inflammation prior to impaired glucose metabolism
is observed and prior to diagnosis of MetS and there-
fore makes them suitable candidates for early biomarkers
in asymptomatic subjects at increased risk of developing
MetS.
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